Outlook Therapeutics, Inc. (OTLK)
Automate Your Wheel Strategy on OTLK
With Tiblio's Option Bot, you can configure your own wheel strategy including OTLK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol OTLK
- Rev/Share 0.0
- Book/Share -1051454.4601
- PB -0.0
- Debt/Equity -0.0084
- CurrentRatio 0.7174
- ROIC -11.0461
- MktCap 71994216.0
- FreeCF/Share -892372.5124
- PFCF -0.0
- PE 2.4558
- Debt/Assets 0.0143
- DivYield 0
- ROE -0.0
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 3
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event
Published: June 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
ISELIN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will participate in a Virtual Investor Lunch Break Event on Wednesday, June 25, 2025 at 12:00 PM ET.
Read More
Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK) 2.8 million injections of repackaged off-label bevacizumab in Europe each year 1 ISELIN, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that LYTENAVA™ (bevacizumab gamma) is now commercially available in Germany and the UK for the treatment of wet age-related macular degeneration (wet AMD).
Read More
Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering
Published: May 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
ISELIN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the pricing of an underwritten public offering of 9,285,714 shares of its common stock, together with accompanying warrants to purchase 18,571,428 shares of its common stock. The combined public offering price of common stock and accompanying warrant is $1.40. The common stock is being sold in combination with an accompanying warrant to purchase two shares of common stock issued for each share of common stock sold. The …
Read More
Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
On-demand video webcast now available here ISELIN, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced it participated in the Virtual Investor "Top 5 for ‘25” On-Demand Conference.
Read More
About Outlook Therapeutics, Inc. (OTLK)
- IPO Date 2016-06-14
- Website https://www.outlooktherapeutics.com
- Industry Biotechnology
- CEO Mr. Lawrence A. Kenyon CPA
- Employees 23